A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Public ClinicalTrials.gov record NCT00781612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Study identification
- NCT ID
- NCT00781612
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 378 participants
Conditions and interventions
Conditions
Interventions
- Docetaxel Drug
- Paclitaxel Drug
- Pertuzumab Drug
- Trastuzumab Drug
- Trastuzumab Emtansine Drug
- Atezolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2008 (Actual)
- Primary completion
- Jun 30, 2027 (Estimated)
- Completion
- Jun 30, 2027 (Estimated)
- Last update posted
- Aug 28, 2026
2008 – 2027
United States locations
- U.S. sites
- 49
- U.S. states
- 23
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Can Care Assoc Med Group Inc | Redondo Beach | California | 90277 | — |
| Univ of Calif, San Francisco | San Francisco | California | 94115 | — |
| Central Coast Medical Oncology | San Luis Obispo | California | 93454 | — |
| UCLA Oncology Office | Santa Monica | California | 90404 | — |
| Stanford Cancer Institute | Stanford | California | 94305-5456 | — |
| Kaiser Permanente - Walnut Creek | Walnut Creek | California | 94596 | — |
| Univ of Colorado Canc Ctr | Aurora | Colorado | 80045 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Center - Denver | Denver | Colorado | 80220 | — |
| Christina Care Institutional Review Board | Newark | Delaware | 19713 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Memorial Cancer Institute at Memorial West | Pembroke Pines | Florida | 33028 | — |
| Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building) | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists - Tampa (Dr. MLK Blvd) | Tampa | Florida | 33607 | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | 30060 | — |
| Kootenai Cancer Center | Post Falls | Idaho | 83854 | — |
| Loyola University Med Center | Maywood | Illinois | 60153 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Hematology-Oncology | Bettendorf | Iowa | 52722 | — |
| Oncology Assoc of Cedar Rapids | Cedar Rapids | Iowa | 52403 | — |
| Anne Arundel Medical Center | Annapolis | Maryland | 21401 | — |
| Johns Hopkins Univ Med Center | Baltimore | Maryland | 21231-1000 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Minnesota Oncology Hematology, Pa | Minneapolis | Minnesota | 55407 | — |
| University of Minnesota. | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Mercy Clinic Cancer & Hematology | Springfield | Missouri | 65804 | — |
| St. John's Mercy Medical Ctr | St Louis | Missouri | 63141 | — |
| Comp Cancer Centers of Nevada | Las Vegas | Nevada | 89148 | — |
| St. Barnabas Health Care Sys | Livingston | New Jersey | 07039 | — |
| Clinical Research Alliance | Lake Success | New York | 11042 | — |
| NS-Long Island Jewish Hlth Sys | Lake Success | New York | 11042 | — |
| Laura and ISAAC Perlmutter Cancer Center at NYU Langone. | New York | New York | 10016 | — |
| Carolina Oncology Specialists, PA - Hickory | Hickory | North Carolina | 28602 | — |
| The Mark H. Zangmeister Ctr | Columbus | Ohio | 43219 | — |
| Northwest Cancer Specialists - Portland (N Broadway) | Portland | Oregon | 97227 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology | Bedford | Texas | 76022 | — |
| Texas Oncology - Dallas Presbyterian Hospital | Dallas | Texas | 75231 | — |
| USO | Plano | Texas | 75075-7787 | — |
| Cancer Therapy & Research Center | San Antonio | Texas | 78229 | — |
| USO - Tyler Cancer Ctr | Tyler | Texas | 75702 | — |
| Uni of Washington Medical Center | Seattle | Washington | 98109-1023 | — |
| Univ of WA Medical Center | Seattle | Washington | 98109 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 130 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00781612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00781612 live on ClinicalTrials.gov.